Javier Olazarán
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Javier Olazarán has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Meritxell Valentí-Soler
Alzheimer Disease Research Unit, CIEN Foundation, Carlos III Institute of Health, Alzheimer Center Reina Sofia Foundation, Madrid, Spain
4 shared publications Pablo Martínez-Martín
4 shared publications- Beatriz León-Salas
Canary Islands Health Research Institute Foundation (FIISC) Tenerife Spain
3 shared publications José Luis Dobato
3 shared publicationsAD Research Unit Investigators
2 shared publicationsBelén González
Alzheimer Disease Research Unit, Alzheimer Center Reina Sofía Foundation, CIEN Foundation, Carlos III Institute of Health, Madrid, Spain
2 shared publications
Latest Publications
- 1 November 2015
- Published by Elsevier in Neurología
- Vol. 30 (9) , 589-591
No hay razones científicas para jubilar al MMSE
- 1 November 2015
- Published by Elsevier in Neurología
- Vol. 30 (9) , 589-591
No hay razones científicas para jubilar al MMSE
- Open Access
- 3 September 2015
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 7, 133
Social robots in advanced dementia
Aims: Testing the effect of the experimental robot-based therapeutic sessions for patients with dementia in: a controlled study of parallel groups of nursing home patients comparing the effects of therapy sessions utilizing a humanoid robot (NAO), an animal-shaped robot (PARO), or a trained dog (DOG), with conventional therapy (CONTROL) on symptoms of dementia; and an experience for patients who attend a day care center, comparing symptom prevalence and severity before and after sessions utilizing NAO and PARO. Methods: In the nursing home, patients were randomly assigned by blocks, based on dementia severity, to one of the 3 therapeutic groups to compare: CONTROL, PARO and NAO (phase 1) and CONTROL, PARO and DOG (phase 2). In the day care center, all patients received therapy with NAO (phase 1) and PARO (phase 2). Therapy sessions were held 2 days/week for 3 months. Evaluation at baseline and follow-up was carried out by blind raters using: the Global Deterioration Scale (GDS), the Severe Mini Mental State Examination (sMMSE), the Mini Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI), the Apathy Scale for Institutionalized Patients with Dementia Nursing Home version (APADEM-NH), the Apathy Inventory (AI) and the Quality of Life Scale (QUALID). Statistical analysis included descriptive statistics and non parametric tests performed by a blinded investigator. Results: In the nursing home, 101 patients (phase 1) and 110 patients (phase 2) were included. There were no significant differences at baseline. The relevant changes at follow-up were: (phase 1) patients in the robot groups showed an improvement in apathy; patients in NAO group showed a decline in cognition as measured by the MMSE scores, but not the sMMSE; the robot groups showed no significant changes between them; (phase 2) QUALID scores increased in the PARO group. In the day care center, 20 patients (phase 1) and 17 patients (phase 2) were included. The main findings were: (phase 1) imp
- 3 September 2015
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 7, 133
Open AccessSocial robots in advanced dementia
Aims: Testing the effect of the experimental robot-based therapeutic sessions for patients with dementia in: a controlled study of parallel groups of nursing home patients comparing the effects of therapy sessions utilizing a humanoid robot (NAO), an animal-shaped robot (PARO), or a trained dog (DOG), with conventional therapy (CONTROL) on symptoms of dementia; and an experience for patients who attend a day care center, comparing symptom prevalence and severity before and after sessions utilizing NAO and PARO. Methods: In the nursing home, patients were randomly assigned by blocks, based on dementia severity, to one of the 3 therapeutic groups to compare: CONTROL, PARO and NAO (phase 1) and CONTROL, PARO and DOG (phase 2). In the day care center, all patients received therapy with NAO (phase 1) and PARO (phase 2). Therapy sessions were held 2 days/week for 3 months. Evaluation at baseline and follow-up was carried out by blind raters using: the Global Deterioration Scale (GDS), the Severe Mini Mental State Examination (sMMSE), the Mini Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI), the Apathy Scale for Institutionalized Patients with Dementia Nursing Home version (APADEM-NH), the Apathy Inventory (AI) and the Quality of Life Scale (QUALID). Statistical analysis included descriptive statistics and non parametric tests performed by a blinded investigator. Results: In the nursing home, 101 patients (phase 1) and 110 patients (phase 2) were included. There were no significant differences at baseline. The relevant changes at follow-up were: (phase 1) patients in the robot groups showed an improvement in apathy; patients in NAO group showed a decline in cognition as measured by the MMSE scores, but not the sMMSE; the robot groups showed no significant changes between them; (phase 2) QUALID scores increased in the PARO group. In the day care center, 20 patients (phase 1) and 17 patients (phase 2) were included. The main findings were: (phase 1) imp
- 8 January 2014
- Published by SAGE Publications in American Journal of Alzheimer's Disease and Other Dementias®
- Vol. 29 (3) , 263-269
Pattern of and Risk Factors for Brain Microbleeds in Neurodegenerative Dementia
A cross-sectional study was conducted to describe the prevalence, locations, and risk factors for brain microbleeds (BMBs) in neurodegenerative dementia. The database of the Alzheimer Center Reina Sofía Foundation was searched, BMBs were described, and the potential associations of BMBs were investigated using univariate statistics. A total of 148 patients (age 81.6 [standard deviation 6.7], 79.1% female) were studied. Prevalence of BMBs was 44.6%. A group of patients with unusually high (ie, ≥4) number of BMBs were identified, which displayed higher number of vascular risk factors and vascular diseases. Brain microbleeds were also associated with ischemic lesions in the basal ganglia (r = .39), clinical diagnosis of Alzheimer’s disease (AD) and cerebrovascular disease (r = .33), cortical infarction (r = .20), and antiaggregant or anticoagulant treatment duration (r = .20). Brain microbleeds are associated with vascular burden and AD diagnosis in old patients with neurodegenerative dementia. More research is warranted regarding the mechanisms and potential clinical implications of these results.
- 8 January 2014
- Published by SAGE Publications in American Journal of Alzheimer's Disease and Other Dementias®
- Vol. 29 (3) , 263-269
Pattern of and Risk Factors for Brain Microbleeds in Neurodegenerative Dementia
A cross-sectional study was conducted to describe the prevalence, locations, and risk factors for brain microbleeds (BMBs) in neurodegenerative dementia. The database of the Alzheimer Center Reina Sofía Foundation was searched, BMBs were described, and the potential associations of BMBs were investigated using univariate statistics. A total of 148 patients (age 81.6 [standard deviation 6.7], 79.1% female) were studied. Prevalence of BMBs was 44.6%. A group of patients with unusually high (ie, ≥4) number of BMBs were identified, which displayed higher number of vascular risk factors and vascular diseases. Brain microbleeds were also associated with ischemic lesions in the basal ganglia (r = .39), clinical diagnosis of Alzheimer’s disease (AD) and cerebrovascular disease (r = .33), cortical infarction (r = .20), and antiaggregant or anticoagulant treatment duration (r = .20). Brain microbleeds are associated with vascular burden and AD diagnosis in old patients with neurodegenerative dementia. More research is warranted regarding the mechanisms and potential clinical implications of these results.
- 1 January 2014
- Vol. 1 (3) , 151-159
Brain Donation by Proxy: Are There Predictors in Neurodegenerative Dementia?
To describe the frequency and predictors of brain donation by relatives in patients with neurodegenerative dementia. Database review and quantitative analysis. The Alzheimer Center Reina Sofia Foundation (ACRSF), a center devoted to the care and research of patients with neurodegenerative dementia. Patients with signed consent for participation in the ACRSF research program. A set of 38 demographic, clinical, and social variables related to patient and closest relative, which were collected by the ACRSF multidisciplinary team upon patient admission. Admission data were available for 198 patients who entered the ACRSF research program; 85 of them (42.9%) died during follow-up. Mean age (SD) at admission was 82.3 (6.8) years and 80.8% of the patients were female. Family link between patient and closest relative was spouse or partner (12.0%), son or daughter (74.9%), or other link (13.1%). Brain was obtained from 56 patients (65.9%). Consent by legal representative and patient's depressive symptoms were more frequent in the donors (p<0.05, corrected) and trend was observed for more aberrant motor symptoms in the donors (p<0.05, uncorrected). A high rate of brain donation was achieved, probably due to the unique characteristics of the ACRSF and consent for research policy. Wish of alleviating suffering, as well as general interest in dementia research, possibly exerted an influence in brain donation. More research is needed to ascertain the values, motivations, and circumstances that may lead to brain donation by proxy in neurodegenerative dementia.
- 1 January 2014
- Vol. 1 (3) , 151-159
Brain Donation by Proxy: Are There Predictors in Neurodegenerative Dementia?
To describe the frequency and predictors of brain donation by relatives in patients with neurodegenerative dementia. Database review and quantitative analysis. The Alzheimer Center Reina Sofia Foundation (ACRSF), a center devoted to the care and research of patients with neurodegenerative dementia. Patients with signed consent for participation in the ACRSF research program. A set of 38 demographic, clinical, and social variables related to patient and closest relative, which were collected by the ACRSF multidisciplinary team upon patient admission. Admission data were available for 198 patients who entered the ACRSF research program; 85 of them (42.9%) died during follow-up. Mean age (SD) at admission was 82.3 (6.8) years and 80.8% of the patients were female. Family link between patient and closest relative was spouse or partner (12.0%), son or daughter (74.9%), or other link (13.1%). Brain was obtained from 56 patients (65.9%). Consent by legal representative and patient's depressive symptoms were more frequent in the donors (p<0.05, corrected) and trend was observed for more aberrant motor symptoms in the donors (p<0.05, uncorrected). A high rate of brain donation was achieved, probably due to the unique characteristics of the ACRSF and consent for research policy. Wish of alleviating suffering, as well as general interest in dementia research, possibly exerted an influence in brain donation. More research is needed to ascertain the values, motivations, and circumstances that may lead to brain donation by proxy in neurodegenerative dementia.
- 1 November 2013
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 57 (3) , 257-262
Quality of life (QoL) in community-dwelling and institutionalized Alzheimer's disease (AD) patients
- 1 November 2013
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 57 (3) , 257-262
Quality of life (QoL) in community-dwelling and institutionalized Alzheimer's disease (AD) patients
- Open Access
- 12 September 2013
- Published by Hindawi Limited in International Journal of Alzheimer's Disease
- Vol. 2013, 1-6
Cumulative Effect of Depression on Dementia Risk
Objective. To analyze a potential cumulative effect of life-time depression on dementia and Alzheimers disease (AD), with control of vascular factors (VFs). Methods. This study was a subanalysis of the Neurological Disorders in Central Spain (NEDICES) study. Past and present depression, VFs, dementia status, and dementia due to AD were documented at study inception. Dementia status was also documented after three years. Four groups were created according to baseline data: never depression (nD), past depression (pD), present depression (prD), and present and past depression (prpD). Logistic regression was used. Results. Data of 1,807 subjects were investigated at baseline (mean age 74.3, 59.3% women), and 1,376 (81.6%) subjects were evaluated after three years. The prevalence of dementia at baseline was 6.7%, and dementia incidence was 6.3%. An effect of depression was observed on dementia prevalence (OR [CI 95%] 1.84 [1.013.35] for prD and 2.73 [1.086.87] for prpD), and on dementia due to AD (OR 1.98 [0.983.99] for prD and OR 3.98 [1.4810.71] for prpD) (fully adjusted models, nD as reference). Depression did not influence dementia incidence. Conclusions. Present depression and, particularly, present and past depression are associated with dementia at old age. Multiple mechanisms, including toxic effect of depression on hippocampal neurons, plausibly explain these associations.
- 12 September 2013
- Published by Hindawi Limited in International Journal of Alzheimer's Disease
- Vol. 2013, 1-6
Open AccessCumulative Effect of Depression on Dementia Risk
Objective. To analyze a potential cumulative effect of life-time depression on dementia and Alzheimers disease (AD), with control of vascular factors (VFs). Methods. This study was a subanalysis of the Neurological Disorders in Central Spain (NEDICES) study. Past and present depression, VFs, dementia status, and dementia due to AD were documented at study inception. Dementia status was also documented after three years. Four groups were created according to baseline data: never depression (nD), past depression (pD), present depression (prD), and present and past depression (prpD). Logistic regression was used. Results. Data of 1,807 subjects were investigated at baseline (mean age 74.3, 59.3% women), and 1,376 (81.6%) subjects were evaluated after three years. The prevalence of dementia at baseline was 6.7%, and dementia incidence was 6.3%. An effect of depression was observed on dementia prevalence (OR [CI 95%] 1.84 [1.013.35] for prD and 2.73 [1.086.87] for prpD), and on dementia due to AD (OR 1.98 [0.983.99] for prD and OR 3.98 [1.4810.71] for prpD) (fully adjusted models, nD as reference). Depression did not influence dementia incidence. Conclusions. Present depression and, particularly, present and past depression are associated with dementia at old age. Multiple mechanisms, including toxic effect of depression on hippocampal neurons, plausibly explain these associations.
- 18 June 2013
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 36 (2) , 297-302
Motor Effects of REAC in Advanced Alzheimer's Disease: Results From a Pilot Trial
We conducted a pilot, randomized, controlled trial to mainly investigate the feasibility, safety, and short-term motor effects of brain stimulation with radio electric asymmetric conveyer (REAC) technology in patients with advanced Alzheimer's diseas
- 18 June 2013
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 36 (2) , 297-302
Motor Effects of REAC in Advanced Alzheimer's Disease: Results From a Pilot Trial
We conducted a pilot, randomized, controlled trial to mainly investigate the feasibility, safety, and short-term motor effects of brain stimulation with radio electric asymmetric conveyer (REAC) technology in patients with advanced Alzheimer's diseas
- 17 December 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 33 (2) , 495-505
Clinical and Anatomical Correlates of Gait Dysfunction in Alzheimer's Disease
We conducted a cross-sectional study to investigate the clinical and anatomical correlates of gait dysfunction in advanced Alzheimer's disease (AD). A comprehensive clinical protocol that included cognitive, functional, behavioral, and motor variable
- 17 December 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 33 (2) , 495-505
Clinical and Anatomical Correlates of Gait Dysfunction in Alzheimer's Disease
We conducted a cross-sectional study to investigate the clinical and anatomical correlates of gait dysfunction in advanced Alzheimer's disease (AD). A comprehensive clinical protocol that included cognitive, functional, behavioral, and motor variable
- Open Access
- 22 September 2012
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders Extra
- Vol. 2 (1) , 400-410
Alzheimer’s Disease with Vascular Component: A Distinct Clinical Entity
Background: Longitudinal reports on the clinical features of patients with Alzheimer’s disease (AD) and concomitant cerebrovascular disease are scarce. Methods: We elaborated a working definition of AD with vascular component (ADVC), and this definition was retrospectively investigated in a cohort of patients with cognitive deterioration who were prescribed a cholinesterase inhibitor during usual practice. Results: A total of 137 patients with probable AD and 66 patients with ADVC were studied during a mean follow-up period of 2.8 years. Univariate analyses demonstrated worse functional evolution and anticipation of psychotic symptoms and agitation in the ADVC group. Conclusions: The present results are consistent with an additive model of predominantly frontal-subcortical vascular damage in AD.
- 22 September 2012
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders Extra
- Vol. 2 (1) , 400-410
Open AccessAlzheimer’s Disease with Vascular Component: A Distinct Clinical Entity
Background: Longitudinal reports on the clinical features of patients with Alzheimer’s disease (AD) and concomitant cerebrovascular disease are scarce. Methods: We elaborated a working definition of AD with vascular component (ADVC), and this definition was retrospectively investigated in a cohort of patients with cognitive deterioration who were prescribed a cholinesterase inhibitor during usual practice. Results: A total of 137 patients with probable AD and 66 patients with ADVC were studied during a mean follow-up period of 2.8 years. Univariate analyses demonstrated worse functional evolution and anticipation of psychotic symptoms and agitation in the ADVC group. Conclusions: The present results are consistent with an additive model of predominantly frontal-subcortical vascular damage in AD.
- 12 January 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 28 (1) , 211-222
Promoting Research in Advanced Dementia: Early Clinical Results of the Alzheimer Center Reina Sofía Foundation
The Alzheimer Center Reina Sofía Foundation (ACRSF) was envisaged to address the complex and multi-disciplinary research and care needs posed by Alzheimer's disease (AD) and other neurodegenerative dementias. Patients may be admitted at ACRSF either
- 12 January 2012
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 28 (1) , 211-222
Promoting Research in Advanced Dementia: Early Clinical Results of the Alzheimer Center Reina Sofía Foundation
The Alzheimer Center Reina Sofía Foundation (ACRSF) was envisaged to address the complex and multi-disciplinary research and care needs posed by Alzheimer's disease (AD) and other neurodegenerative dementias. Patients may be admitted at ACRSF either